Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome?

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 4, 2009, Pages 1089-1091

  Mantzoros, Christos S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; METFORMIN; PIOGLITAZONE; PLACEBO; RECOMBINANT LEPTIN; ROSIGLITAZONE;

CLINICAL TRIAL; DISEASE ASSOCIATION; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOATROPHY; METABOLIC SYNDROME X; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL;

EID: 65249122675     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0340     Document Type: Editorial

References (21)

1. Grinspoon S, Carr A 2005 Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352:48-62
2. Leow MK, Addy CL, Mantzoros CS 2003 Clinical review 159: human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 88:1961-1976
3. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, Riesen W, Nicod P, Darioli R, Telenti A, Mooser V; Swiss HIV Cohort Study 2001 Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS 15:329-334
4. NagyGS,TsiodrasS,Martin LD,Avihingsanon A,Gavrila A,HsuWC,Karchmer AW, Mantzoros CS 2003 Human immunodeficiency virus type 1-related lipoat- rophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 36:795-802
5. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS 2003 Hypoadiponectinemia is associated with insulin resistance, hypertriglyc- eridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 88:627-636
6. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T 2001 The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoat- rophy and obesity. Nat Med 7:941-946
7. Petersen KF,Oral EA,Dufour S,Befroy D,Ariyan C,Yu C,Cline GW,De Paoli AM, Taylor SI, Gorden P, Shulman GI 2002 Leptin reverses insulin resistance
8. and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109: 1345-1350
9. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P 2005 Long-term efficacy of leptin replacement in patients with generalized lipodys- trophy. Diabetes 54:1994-2002
10. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A 2002 Leptin-replace- ment therapy for lipodystrophy. N Engl J Med 346:570 -578
11. Andreev VP, Paz-Filho G, Wong ML, Licinio J 2009 Deconvolution of insulin secretion, insulin hepatic extraction post-hepatic delivery rates and sensitivity during 24-hour standardized meals: time course of glucose homeostasis in leptin replacement treatment. Horm Metab Res 41:142-151
12. Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, Tanaka T, Chusho H, Miyazawa T, Hayashi T, Hosoda K, Ogawa Y, DePaoli AM, ssssFukushima M, Nakao K 2007 Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 92:532-541
13. Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, Kleiner DE, Gorden P 2005 Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41:753-760
14. MulliganK,Khatami H,Schwarz JM,Sakkas GK,DePaoli AM,Tai VW,Wen MJ, Lee GA, Grunfeld C, Schambelan M 2009 The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with HIV-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 94:1137-1144
15. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS 2006 Recombinant methinoyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 91:2605-2611
16. Bluher S, Mantzoros CS 2009 Leptin in humans: lessons from translational research. Am JClin Nutr 89:991S-997S
17. Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, Hemphill L, Lee H, Grinspoon S 2008 Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 300:509-519
18. Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, Saag M, BockD, Simons G, GertnerJM 2004Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 35:239-297
19. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S2007 Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357: 2359-2370
20. Brennan AM, Lee JH, Tsiodras S, Chan JL, Doweiko J, Chimienti SN, Wadhwa SG, Karchmer AW, Mantzoros CS 2009 r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans. Eur J Endocrinol 160:173-176
21. Gavrila A, Hsu W, Tsiodras S, Doweiko J, Gautam S, Martin L, Moses AC, Karchmer AW, Mantzoros CS 2005 Improvement in highly active antiretro- viral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 *2 factorial, randomized, double-blinded, placebo- controlled trial. Clin Infect Dis 40:745-749